Deep Track Capital LP bought a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 169,132 shares of the biopharmaceutical company's stock, valued at approximately $6,630,000. Deep Track Capital LP owned 0.22% of Xenon Pharmaceuticals at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in XENE. Barclays PLC grew its stake in Xenon Pharmaceuticals by 1,275.5% in the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company's stock valued at $590,000 after acquiring an additional 13,903 shares during the period. Harbor Capital Advisors Inc. grew its position in Xenon Pharmaceuticals by 3.7% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,818 shares of the biopharmaceutical company's stock valued at $1,953,000 after purchasing an additional 1,755 shares during the period. Elmwood Wealth Management Inc. grew its position in Xenon Pharmaceuticals by 44.7% in the 4th quarter. Elmwood Wealth Management Inc. now owns 11,007 shares of the biopharmaceutical company's stock valued at $431,000 after purchasing an additional 3,400 shares during the period. Assenagon Asset Management S.A. increased its stake in Xenon Pharmaceuticals by 12.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 238,522 shares of the biopharmaceutical company's stock valued at $9,350,000 after purchasing an additional 26,235 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Xenon Pharmaceuticals by 72.3% in the fourth quarter. SG Americas Securities LLC now owns 13,293 shares of the biopharmaceutical company's stock valued at $521,000 after buying an additional 5,577 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.
Xenon Pharmaceuticals Stock Down 1.2 %
Shares of Xenon Pharmaceuticals stock traded down $0.41 on Friday, reaching $35.13. The company's stock had a trading volume of 1,055,391 shares, compared to its average volume of 472,575. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of -12.46 and a beta of 1.21. Xenon Pharmaceuticals Inc. has a 52 week low of $26.74 and a 52 week high of $46.00. The firm's fifty day simple moving average is $34.59 and its two-hundred day simple moving average is $38.33.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($0.89) by $0.05. As a group, research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.
Analysts Set New Price Targets
A number of analysts have commented on the company. The Goldman Sachs Group decreased their price objective on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a report on Thursday, April 17th. Deutsche Bank Aktiengesellschaft assumed coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They issued a "buy" rating and a $67.00 price target for the company. StockNews.com lowered shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, May 2nd. William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Monday. Finally, Chardan Capital began coverage on shares of Xenon Pharmaceuticals in a report on Wednesday. They set a "buy" rating and a $55.00 price target on the stock. One research analyst has rated the stock with a sell rating and eleven have given a buy rating to the company. According to MarketBeat, Xenon Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $56.60.
Read Our Latest Report on XENE
Xenon Pharmaceuticals Company Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Read More
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
